Candel Therapeutics (CADL) Short term Debt (2023 - 2025)

Candel Therapeutics (CADL) has 3 years of Short term Debt data on file, last reported at $4.2 million in Q3 2025.

• For the quarter ending Q3 2025, Short term Debt fell 57.11% year-over-year to $4.2 million; the trailing twelve-month figure through Sep 2025 stood at $4.2 million (down 57.11% YoY), and the FY2024 full-year result was $9.9 million, up 11.27% from the prior year.
• Short term Debt slipped to $4.2 million in Q3 2025, from $6.7 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.9 million in Q4 2024 to a low of $1.3 million in Q1 2023.
• A 3-year average of $7.2 million and a median of $8.9 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt surged 679.49% in 2024 and sank 57.11% in 2025, its largest moves.
• Tracing CADL's Short term Debt over 3 years: stood at $8.9 million in 2023, then increased by 11.27% to $9.9 million in 2024, then sank by 57.3% to $4.2 million in 2025.
• Business Quant data shows CADL's Short term Debt at $4.2 million in Q3 2025, $6.7 million in Q2 2025, and $9.2 million in Q1 2025.